Hong Kong Laureate Forum: Calling Outstanding Young Scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences!
14.9.2020 04:00:00 EEST | Business Wire | Press release
Open application for the inaugural Hong Kong Laureate Forum starts today and will end on 13 December 2020. We welcome undergraduates, postgraduates and PhD graduates who are aged 35 or below and studying or conducting research in Astronomy, Life Science and Medicine, Mathematical Sciences or other closely related subjects to apply for the Hong Kong Laureate Forum and become one of the 200 selected young scientists to be inspired by world-renowned Shaw Laureates. Eligible Young Scientists are welcome to complete and submit their applications via this link: https://hklaureateforum.org/en/application-form
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200913005003/en/
Open Application from 14 September to 13 December 2020 (Graphic: Business Wire)
The inaugural Hong Kong Laureate Forum will be held on 15-20 November 2021 in Hong Kong. Being Asia’s world city and a city long celebrated for its vibrancy, Hong Kong is an ideal place for such an international gathering.
During a week-long programme, there will be ample opportunities for exchanges between participating Shaw Laureates and the young scientists. Apart from plenary lectures, panel discussions and parallel group sessions conducted by Shaw Laureates and other distinguished scientists, the programme will also offer informal and cozy gatherings with plenty of chances of networking and dialogues. There will also be presentation sessions for selected young scientists to showcase their latest research ideas to spark intellectual exchanges.
Mrs DO PANG Wai Yee, Secretary-General of the Council of the Hong Kong Laureate Forum (the HKLF) said: “As of today, we have received positive response from over 20 Shaw Laureates, including several Nobel Laureates and Fields Medalist, to join our Forum.”
Professor Steven Balbus, Shaw Laureate in Astronomy 2013 remarked: “I have nothing but pleasant memories of Hong Kong and I look forward to many more. It’s a city that feels exciting and that things are working. I think the Hong Kong Laureate Forum is going to be extremely exciting and a very special program that’s going to capture the imagination of the public.”
Professor Simon White, Shaw Laureate in Astronomy 2017 said: “I think the significance of the Shaw Prize is because it makes certain aspects of science visible to a wider public. And this fuels the curiosity which leads people to do science, which pushes them to improve their capabilities. I hope the Hong Kong Laureate Forum will make young people really enthusiastic and curious about science.”
The most outstanding 200 young scientists will be selected to join the inaugural Forum by a Scientific Review Panel comprising local and non-local academics. All applicants, either successful or not, will receive email notification in April 2021.
For enquiries regarding application, please contact Forum Programmes and Participants Enquiry at programme@hklaureateforum.org.
Background
The Hong Kong Laureate Forum is an annual scientific exchange event organized by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by Lee Shau Kee Foundation. The important partner of the HKLF is The Shaw Prize Foundation which organizes the annual international award The Shaw Prize.
To the Press
With this press release, we would like to extend an invitation to the Press to attend and report on the inaugural Hong Kong Laureate Forum.
Website:
https://www.hklaureateforum.org
Facebook:
https://www.facebook.com/HKLaureateForum
Twitter:
https://www.twitter.com/HKLaureateForum
Weibo:
https://www.weibo.com/hklaureateforum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200913005003/en/
Contact information
Forum Programmes and Participants Enquiry
Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom